Nektar Therapeutics (NKTR) Shares are Up 13.75%

Nektar Therapeutics (NKTR) : Traders are bullish on Nektar Therapeutics (NKTR) as it has outperformed the S&P 500 by a wide margin of 16.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 13.83%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.75% in the last 1 week, and is up 20.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 14.61% and the 50-Day Moving Average is 15.2%. Nektar Therapeutics is up 10.27% in the last 3-month period. Year-to-Date the stock performance stands at 2.61%.


Nektar Therapeutics (NASDAQ:NKTR): stock turned positive on Friday. Though the stock opened at $16.09, the bulls momentum made the stock top out at $17.37 level for the day. The stock recorded a low of $16.08 and closed the trading day at $17.29, in the green by 7.39%. The total traded volume for the day was 2,670,553. The stock had closed at $16.1 in the previous days trading.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.